ERAS
Price:
$13.67
Market Cap:
$4.25B
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was...[Read more]
Industry
Biotechnology
IPO Date
2021-07-16
Stock Exchange
NASDAQ
Ticker
ERAS
According to Erasca, Inc.’s latest financial reports and current stock price. The company's current ROE is -77.01%. This represents a change of 319.34% compared to the average of -18.37% of the last 4 quarters.
The mean historical ROE of Erasca, Inc. over the last ten years is -29.71%. The current -77.01% ROE has changed 159.26% with respect to the historical average. Over the past ten years (40 quarters), ERAS's ROE was at its highest in in the March 2020 quarter at 0%. The ROE was at its lowest in in the December 2020 quarter at -56.77%.
Average
-29.71%
Median
-38.30%
Minimum
-94.64%
Maximum
88.50%
Discovering the peaks and valleys of Erasca, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 119.24%
Maximum Annual ROE = 88.50%
Minimum Annual Increase = -206.93%
Minimum Annual ROE = -94.64%
| Year | ROE | Change |
|---|---|---|
| 2025 | -38.30% | 0.34% |
| 2024 | -38.17% | -3.33% |
| 2023 | -39.48% | -33.03% |
| 2022 | -58.95% | 119.24% |
| 2021 | -26.89% | -71.59% |
| 2020 | -94.64% | -206.93% |
The current ROE of Erasca, Inc. (ERAS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-38.65%
5-year avg
-40.36%
10-year avg
-29.71%
Erasca, Inc.’s ROE is greater than Astria Therapeutics, Inc. (-45.01%), greater than ArriVent BioPharma, Inc. Common Stock (-48.98%), greater than MoonLake Immunotherapeutics (-85.61%), greater than Iovance Biotherapeutics, Inc. (-50.17%), less than MeiraGTx Holdings plc (474.91%), greater than MBX Biosciences, Inc. Common Stock (-24.50%), greater than CytomX Therapeutics, Inc. (-36.61%), greater than Corvus Pharmaceuticals, Inc. (-38.92%), greater than Arvinas, Inc. (-44.39%), greater than Valneva SE (-106.22%),
| Company | ROE | Market cap |
|---|---|---|
| -45.01% | $718.13M | |
| -48.98% | $1.48B | |
| -85.61% | $1.41B | |
| -50.17% | $1.40B | |
| 474.91% | $1.05B | |
| -24.50% | $1.45B | |
| -36.61% | $474.43M | |
| -38.92% | $1.00B | |
| -44.39% | $494.88M | |
| -106.22% | $510.15M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Erasca, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Erasca, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Erasca, Inc.'s ROE?
How is the ROE calculated for Erasca, Inc. (ERAS)?
What is the highest ROE for Erasca, Inc. (ERAS)?
What is the 3-year average ROE for Erasca, Inc. (ERAS)?
What is the 5-year average ROE for Erasca, Inc. (ERAS)?
How does the current ROE for Erasca, Inc. (ERAS) compare to its historical average?